Literature DB >> 23823658

Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.

L Olsson1, A Castor2, M Behrendtz3, A Biloglav1, E Forestier4, K Paulsson1, B Johansson5.   

Abstract

Despite the favorable prognosis of childhood acute lymphoblastic leukemia (ALL), a substantial subset of patients relapses. As this occurs not only in the high risk but also in the standard/intermediate groups, the presently used risk stratification is suboptimal. The underlying mechanisms for treatment failure include the presence of genetic changes causing insensitivity to the therapy administered. To identify relapse-associated aberrations, we performed single-nucleotide polymorphism array analyses of 307 uniformly treated, consecutive pediatric ALL cases accrued during 1992-2011. Recurrent aberrations of 14 genes in patients who subsequently relapsed or had induction failure were detected. Of these, deletions/uniparental isodisomies of ADD3, ATP10A, EBF1, IKZF1, PAN3, RAG1, SPRED1 and TBL1XR1 were significantly more common in B-cell precursor ALL patients who relapsed compared with those remaining in complete remission. In univariate analyses, age (≥10 years), white blood cell counts (>100 × 10(9)/l), t(9;22)(q34;q11), MLL rearrangements, near-haploidy and deletions of ATP10A, IKZF1, SPRED1 and the pseudoautosomal 1 regions on Xp/Yp were significantly associated with decreased 10-year event-free survival, with IKZF1 abnormalities being an independent risk factor in multivariate analysis irrespective of the risk group. Older age and deletions of IKZF1 and SPRED1 were also associated with poor overall survival. Thus, analyses of these genes provide clinically important information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23823658     DOI: 10.1038/leu.2013.206

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  51 in total

1.  Expression of adducin genes during erythropoiesis: a novel erythroid promoter for ADD2.

Authors:  Mustafa N Yenerel; I Birgitta Sundell; Joleen Weese; Michael Bulger; Diana M Gilligan
Journal:  Exp Hematol       Date:  2005-07       Impact factor: 3.084

Review 2.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

3.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Authors:  R P Kuiper; E Waanders; V H J van der Velden; S V van Reijmersdal; R Venkatachalam; B Scheijen; E Sonneveld; J J M van Dongen; A J P Veerman; F N van Leeuwen; A Geurts van Kessel; P M Hoogerbrugge
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

4.  The leukemia-associated protein Btg1 and the p53-regulated protein Btg2 interact with the homeoprotein Hoxb9 and enhance its transcriptional activation.

Authors:  D Prévôt; T Voeltzel; A M Birot; A P Morel; M C Rostan; J P Magaud; L Corbo
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

5.  Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.

Authors:  M G Loudin; J Wang; H-C Eastwood Leung; S Gurusiddappa; J Meyer; G Condos; D Morrison; A Tsimelzon; M Devidas; N A Heerema; A J Carroll; S E Plon; S P Hunger; G Basso; A Pession; D Bhojwani; W L Carroll; K R Rabin
Journal:  Leukemia       Date:  2011-06-07       Impact factor: 11.528

6.  Glucocorticoid-induced glucocorticoid-receptor expression and promoter usage is not linked to glucocorticoid resistance in childhood ALL.

Authors:  Wim J E Tissing; Jules P P Meijerink; Bas Brinkhof; Mathilde J C Broekhuis; Renee X Menezes; Monique L den Boer; Rob Pieters
Journal:  Blood       Date:  2006-03-30       Impact factor: 22.113

7.  Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

Authors:  Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

8.  Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin
Journal:  Nat Genet       Date:  2009-10-18       Impact factor: 38.330

9.  NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15).

Authors:  Idoya Lahortiga; José L Vizmanos; Xabier Agirre; Iria Vázquez; Juan C Cigudosa; María J Larrayoz; Francisco Sala; Ana Gorosquieta; Katy Perez-Equiza; María J Calasanz; María D Odero
Journal:  Cancer Res       Date:  2003-06-15       Impact factor: 12.701

10.  Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.

Authors:  Paola Ballerini; Judith Landman-Parker; Jean Michel Cayuela; Vahid Asnafi; Myriam Labopin; Virginie Gandemer; Yves Perel; Gérard Michel; Thierry Leblanc; Claudine Schmitt; Sylvie Fasola; Anne Hagemejier; François Sigaux; Marie Françoise Auclerc; Luc Douay; Guy Leverger; André Baruchel
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941

View more
  26 in total

1.  IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population.

Authors:  Gholamreza Bahari; Mohammad Hashemi; Majid Naderi; Mohsen Taheri
Journal:  Tumour Biol       Date:  2016-01-21

2.  Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.

Authors:  Setareh Safavi; Markus Hansson; Karin Karlsson; Andrea Biloglav; Bertil Johansson; Kajsa Paulsson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

Review 3.  TBL1XR1 in physiological and pathological states.

Authors:  Jian Yi Li; Garrett Daniels; Jing Wang; Xinmin Zhang
Journal:  Am J Clin Exp Urol       Date:  2015-04-25

Review 4.  Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia.

Authors:  Rajesh Somasundaram; Mahadesh A J Prasad; Jonas Ungerbäck; Mikael Sigvardsson
Journal:  Blood       Date:  2015-05-19       Impact factor: 22.113

5.  Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.

Authors:  Courtney L Jones; Teena Bhatla; Roy Blum; Jinhua Wang; Steven W Paugh; Xin Wen; Wallace Bourgeois; Danielle S Bitterman; Elizabeth A Raetz; Debra J Morrison; David T Teachey; William E Evans; Michael J Garabedian; William L Carroll
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

6.  13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking.

Authors:  Minjun Yang; Setareh Safavi; Eleanor L Woodward; Nicolas Duployez; Linda Olsson-Arvidsson; Jonas Ungerbäck; Mikael Sigvardsson; Marketa Zaliova; Jan Zuna; Thoas Fioretos; Bertil Johansson; Karolin H Nord; Kajsa Paulsson
Journal:  Blood       Date:  2020-08-20       Impact factor: 22.113

Review 7.  Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.

Authors:  Michelle L Churchman; Charles G Mullighan
Journal:  Exp Hematol       Date:  2016-11-16       Impact factor: 3.084

8.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

9.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

10.  Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.

Authors:  Zheng Ge; Chunhua Song; Yali Ding; Bi-Hua Tan; Dhimant Desai; Arati Sharma; Raghavendra Gowda; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Soumya Iyer; Pavan Kumar Dhanyamraju; Yuka Imamura; Daniel Bogush; Yevgeniya Bamme; Yiping Yang; Mario Soliman; Shriya Kane; Elanora Dovat; Joseph Schramm; Tommy Hu; Mary McGrath; Zissis C Chroneos; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Leukemia       Date:  2021-02-02       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.